Retraction:

Peng Lv^1,2, Yue Wang³, Jie Ma¹, Zheng Wang¹, Jing-Li Li³, Christopher S. Hong⁴, Zhengping Zhuang⁴ and Yi-Xin Zeng^1,5,6

¹Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS) ,Beijing , People’s Republic of China
²Beijing Neurosurgical Institute, Capital Medical University, Beijing, People’s Republic of China
³Institute for Medical Device Standardization Administration, National Institutes for Food and Drug Control, Beijing , People’s Republic of China
⁴Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD ,USA
⁵Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong , People’s Republic of China
⁶State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong , People’s Republic of China

Published: May 19, 2025

Copyright: © 2025 Lv et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: ​Oncotarget has completed its investigation of this paper. Our review identified several instances of duplicated western blot images within Figure 7. The first author, Peng Lv, has acknowledged these errors and has requested a retraction of the paper on behalf of all co-authors. In light of these facts, the Editorial decision was made to retract this paper. All authors agreed with the decision.

Original article: Oncotarget. 2014; 5:7512-7524. DOI: https://doi.org/10.18632/oncotarget.2258.